The receiver operating characteristic (ROC) curves built with 215 cases at SYSUCC2 as the model set, 102 cases at CHCAMS as the validation set and combined samples of both sets yielded area under the ROC curves (AUCs) of 0.819 ( P <0.0001, 95% CI=0.761-0.868), 0.808 ( P <0.0001, 95% CI=0.718-0.879) and 0.811 ( P <0.0001, 95% CI=0.764-0.853), respectively, indicating a highly significant association between serum piR-54265 levels and disease progression or control rate of chemotherapy in CRC patients ( Figure 6 I ).
← all excerpts
PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma.
1
—
—